Grant: Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
McGill University
$135,000.00
Targeting the Mycobacterial Proteasome System to Fight Antimicrobial-Resistant Tuberculosis
EF 2023-24
Résumé
Tuberculosis (TB) is a devastating infectious disease claiming the lives of over 1.5 million people annually. Current treatments targeting the causative agent, Mycobacterium tuberculosis (Mtb), are being exhausted due to the emergence of drug resistant strains. If left untreated, a single person can infect up to 15 people per year, and in Canada, Indigenous populations face infection rates 300× greater than non-Indigenous persons. Thus, new therapeutics targeting Mtb are essential to combat the TB pandemic. Rather than designing novel antibacterial compounds, I propose to adapt a proven anti-cancer drug, bortezomib, to target Mtb as an anti-virulence compound. Because anti-virulence compounds do not kill bacteria, but instead disarm them, allowing the more efficient clearing of pathogens by our immune system, developing resistance is anticipated to be less facile. Bortezomib works by inhibiting the human proteasome, an important machinery for recycling damaged proteins. Proteasome inhibition leads to the accumulation of damaged proteins, thereby resulting in cell death. Our data demonstrate that bortezomib can also target the Mtb proteasome, albeit with modest potency. I hypothesize that elucidating the specific binding interactions of bortezomib against the Mtb proteasome can guide the development of next-generation anti-virulence compounds for TB treatment. My research will employ state-of-the-art structural biology, biochemical, and microbiological tools to characterize the interaction between the Mtb proteasome and bortezomib at the atomic-level. Leveraging this knowledge, we will collaborate with medicinal chemists for the rational design of potent small-molecule inhibitors specific to the Mtb proteasome. Ultimately, I aim to develop a novel therapeutic for TB treatment, benefitting both Canadian and global health.
Programme
Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
497744
Name
Forrester Taylor
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Targeting the Mycobacterial Proteasome System to Fight Antimicrobial-Resistant Tuberculosis
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
Keyworddelim
Antimicrobial Resistance; Cryogenic Electron Microscopy; Crystallography; Hydrogen Deuterium Exchange Mass Spectrometry; Mycobacterium Tuberculosis; Proteasome; Rational Design Of Therapeutics; Structural Biology; Tuberculosis Pandemic
Abstract
Tuberculosis (TB) is a devastating infectious disease claiming the lives of over 1.5 million people annually. Current treatments targeting the causative agent, Mycobacterium tuberculosis (Mtb), are being exhausted due to the emergence of drug resistant strains. If left untreated, a single person can infect up to 15 people per year, and in Canada, Indigenous populations face infection rates 300× greater than non-Indigenous persons. Thus, new therapeutics targeting Mtb are essential to combat the TB pandemic. Rather than designing novel antibacterial compounds, I propose to adapt a proven anti-cancer drug, bortezomib, to target Mtb as an anti-virulence compound. Because anti-virulence compounds do not kill bacteria, but instead disarm them, allowing the more efficient clearing of pathogens by our immune system, developing resistance is anticipated to be less facile. Bortezomib works by inhibiting the human proteasome, an important machinery for recycling damaged proteins. Proteasome inhibition leads to the accumulation of damaged proteins, thereby resulting in cell death. Our data demonstrate that bortezomib can also target the Mtb proteasome, albeit with modest potency. I hypothesize that elucidating the specific binding interactions of bortezomib against the Mtb proteasome can guide the development of next-generation anti-virulence compounds for TB treatment. My research will employ state-of-the-art structural biology, biochemical, and microbiological tools to characterize the interaction between the Mtb proteasome and bortezomib at the atomic-level. Leveraging this knowledge, we will collaborate with medicinal chemists for the rational design of potent small-molecule inhibitors specific to the Mtb proteasome. Ultimately, I aim to develop a novel therapeutic for TB treatment, benefitting both Canadian and global health.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Forrester, Taylor
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~